Results 141 to 150 of about 1,887 (161)
The clinical positioning of telavancin in Europe
International Journal of Antimicrobial Agents, 2015 Telavancin was the first marketed lipoglycopeptide. Although licensed in Europe in 2011 for the treatment of nosocomial pneumonia caused by meticillin-resistant Staphylococcus aureus (MRSA), it did not become clinically available until March 2014.
Antoni Torres +2 more
exaly +2 more sources
Telavancin: A novel lipoglycopeptide antimicrobial agent
American Journal of Health-System Pharmacy, 2007 Purpose. The pharmacology, activity, pharmacokinetics, pharmacodynamics, clinical efficacy, safety, dosage, and place in therapy of telavancin are reviewed. Summary.
exaly +2 more sources
Clinical Infectious Diseases, 2015 Staphylococcus aureus bacteremia (SAB) is one of the most common serious bacterial infections and the most frequent invasive infection due to methicillin-resistant S. aureus (MRSA).
Matteo Bassetti +2 more
exaly +2 more sources
Antimicrobial Agents and Chemotherapy, 2017 The pharmacodynamics of telavancin and vancomycin were compared using neutropenic murine thigh and lung infection models. Four Staphylococcus aureus strains were included.
Alexander J Lepak +2 more
exaly +2 more sources
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Telavancin: mechanisms of action, in vitro activity, and mechanisms of resistance.
Clinical Infectious Diseases, 2015James A. Karlowsky, Kim Nichol
exaly
Dalbavancin and telavancin: novel lipoglycopeptides for the treatment of Gram-positive infections
Expert Review of Anti-Infective Therapy, 2008James A. Karlowsky +1 more
exaly
Outpatient treatment of osteomyelitis with telavancin
International Journal of Antimicrobial Agents, 2017Claudia P Schroeder, Lucinda Van Anglen
exaly